CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20,000 enrolled
Drug / intervention
suPAR measurementbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02643459
NCT02643459N/ACompleted
CompareCT.gov

Introduction of Soluble Urokinase Plasminogen Activating Receptor in Acute Care as a Prognostic Biomarker to Strengthen Risk Stratification of Acutely Admitted Patients

Herlev Hospital·interventional·Posted Dec 31, 2015·Updated Mar 9, 2021

In Brief

A clinical study evaluating suPAR measurement for Triage and Risk Stratification With Biomarker. Completed, enrolled 20,000 participants across 1 site.

Detailed Summary

Will clinical outcome for patients be improved if triage in Acute wards and Emergency rooms is supplemented with a prognostic biomarker?

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTriage, Risk Stratification With Biomarker
CountriesDenmark
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 31, 2015
Enrollment StartJan 1, 2016
Primary CompletionApr 6, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.5 years ago

Interventions

suPAR measurementbehavioral

The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.